For much of the past five years, the cannabis industry has been defined by disappointment. Public equities are down approximately
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug
Today’s cannabis news is dominated by rescheduling momentum, with operators racing to secure DEA Schedule III status even as the White House raises fresh concerns over high-potency products, while the UK, Brazil and Idaho underline how rapidly access is broadening on multiple fronts.
Cannabis drugmakers prepare for IPOs, nearly 400 operators rush to register with the DEA, microdosing data reframes consumer use patterns, and regulators from Israel to the Bahamas reshape their frameworks as Schedule III aftershocks ripple worldwide.
Reclassification confusion, an IPO revival in cannabis pharma and a contentious DEA registration form dominate today’s cannabis news, alongside fresh European consolidation and a return of investor focus on the sector’s ETFs.
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling
Today’s cannabis briefing covers the fallout from the US Justice Department’s Schedule III order, fresh travel guidance for UK medical patients, California’s ten-year legalisation milestone, environmental scrutiny at a Trulieve mega-grow, and a notable state-level legalisation recommendation in North Carolina.
Last week’s rescheduling announcement has placed a spotlight firmly on the medical cannabis arms of North America’s largest operators. With
For many, last week’s rescheduling announcement threw a spanner in the works. The US medical cannabis market, for now the
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling
The White House’s commitment to push through rescheduling has been challenged by a Democratic Senator, who has demanded answers on
The Trump administration’s continued inaction on its promise to push ahead with the highly anticipated cannabis rescheduling project is now
US cannabis rescheduling, much like President Donald Trump who is rightly credited for finally pushing it forward, has sucked all
It is now nearly two months since President Donald Trump surprised the global cannabis industry by signing an executive order to drag the highly-anticipated cannabis rescheduling
President Donald Trump’s executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled
After two years of speculation, rumours, stock swings, broken promises, and political theatre, President Donald Trump officially signed an executive
Cannabis Rescheduling fervour has once again reached dramatic levels following media reports that President Donald Trump is considering pushing through
We won’t spam you
